Vimarsana
Biggest News Aggregation in the World

Page 12 - Nat Commun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nat Commun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nat Commun Today - Breaking & Trending Today

Lithium-Sulfur Battery Breakthrough Could Quintuple EV Range - Vimarsana News

Lithium-Sulfur Battery Breakthrough Could Quintuple EV Range

A team of researchers at the University of Michigan has created a next-generation lithium-sulfur battery using recycled Kevlar.

Brooke Gardner Probes the Cell's Peroxisomes | The Scientist Magazine® - Vimarsana News

Brooke Gardner Probes the Cell's Peroxisomes | The Scientist Magazine®

The University of California, Santa Barbara, cell biologist is investigating the formation and functions of the peroxisome, an organelle which exists in many copies in each cell and can be created, lost, or altered to meet the cell’s metabolic needs.

CODE RED: Climate Change Is Destroying Our Health, Says Lancet - Vimarsana News

CODE RED: Climate Change Is Destroying Our Health, Says Lancet

The Lancet warns that climate change is getting worse and this will exacerbate the health conditions of communities across the globe.

Splitting Up the Sensors in NASA's InSight Mission - Vimarsana News

Splitting Up the Sensors in NASA's InSight Mission

Learn more about how sensor technology in NASA's InSight mission is measuring the "vital signs" of Mars

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection - Vimarsana News

Frontiers | Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Tw...